← SynDRA
VALGANCICLOVIR
SynDRA canonical compound SYN0023529 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Mechanism of action | DNA synthesis inhibitor |
|---|
| Indication | cytomegalovirus (CMV) |
|---|
| Disease area | infectious disease |
|---|
All known targets
Mechanisms of action (all sources)
- DNA synthesis inhibitor
- Inhibitor
Drug classes
- DNA Polymerase Inhibitors
- Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
- Anti-Infective Agents
- Antiviral Agents
ATC classes
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- valganciclovir hydrochloride
- valganciclovir HCl
- Cymeval
- RS 79070
- RO1079070/194
- Valcyte (TN)
- Valganciclovir (INN)
- Valganciclovir (Oral)
- Valganciclovir [INN:BAN]
- L-Valine, ester with ganciclovir
- [2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate
- L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester
- 5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one
- GCU97FKN3R
- CHEBI:63635
- valganciclovirum
- RefChem:56199
- Ganciclovir L valyl Ester
- DTXCID3028263
- J05AB14
- VALGANCICLOVIR [INN]
- NCGC00168779-01
- UNII-GCU97FKN3R
- HSDB 8085
- RS-79070
- VALGANCICLOVIR [MI]
- SCHEMBL28996
- SCHEMBL28998
- VALGANCICLOVIR [VANDF]
- GTPL4716
- orb1688778
- VALGANCICLOVIR [WHO-DD]
- SCHEMBL12672612
- GLXC-22223
- HY-A0032
- EBC-26707
- AKOS015896083
- AKOS015966553
Reported adverse events
- Insomnia
- Nausea
- Pyrexia
- Tremor
- Vomiting
- Headache
- Neutropenia
- Retinal detachment
- Thrombocytopenia
- Abdominal pain
- Agranulocytosis
- Gastrointestinal disorder
Look up VALGANCICLOVIR in the interactive SynDRA portal →